Cancer Genomics for Precision Immunotherapy Lab
About our lab
Our laboratory conducts comprehensive translational research focusing on patients with lung cancer, particularly those treated with targeted therapy or immunotherapy. Through these multidisciplinary efforts, we aim to realize the concept of 'From bench to bedside', bridging fundamental discoveries with clinical applications in precision oncology.
We perform genomic and transcriptomic profiling using next-generation sequencing (NGS) on DNA and RNA isolated from patient-derived specimens, including blood, tissue, and pleural effusion collected before and after treatment. By investigating genetic alterations and transcriptional changes, we seek to elucidate the molecular mechanisms underlying lung cancer development and progression, identify biomarkers for early diagnosis and prognosis, and predict patient-specific drug responses. Furthermore, we develop computational algorithms for neoantigen discovery based on our clinico-multiomics database, aiming to predict therapeutic responses to immune checkpoint inhibitors and advance personalized medicine in cancer immunotherapy.
Currently, our laboratory possesses one of the world's largest clinico-multiomics database from patients treated with immunotherapy, providing a foundation for diverse translational research intiatives. Leveraging these extensive resources, we are commited to cultivating interdisciplinary scientists through close, hands-on mentorship and direct research guidance from the prinicipal investigator, in collaboration with leading domestic and international reserach groups.